Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 18/20 | 0.81 |
| ▸ | INSR | P06213 | 11/20 | 0.81 |
| ▸ | IGF1R | P08069 | 6/20 | 0.81 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | ROS1 | P08922 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916412 | 0.90 | ALK (0.81) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL11900462 | 0.90 | ALK (1.00) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL15219334 | 0.88 | ALK (0.78) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL11916450 | 0.88 | ALK (0.78) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL11916581 | 0.86 | ALK (0.75) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL11916600 | 0.85 | ALK (0.74) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL11916497 | 0.85 | ALK (0.90) | ALKINSRIGF1REGFRROS1 | |
| SCHEMBL11916589 | 0.83 | ALK (0.79) | ALKINSRIGF1R | |
| SCHEMBL11901034 | 0.83 | ALK (0.87) | ALKINSRIGF1R | |
| SCHEMBL11916475 | 0.83 | ALK (0.87) | ALKINSRIGF1RZAP70EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | ALK 370/4885INSR 751/4885IGF1R 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.